Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C32H38N2O8 |
Molecular Weight | 578.6527 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]4([H])N(CCC5=C4NC6=C5C=CC=C6)C2
InChI
InChIKey=CVBMAZKKCSYWQR-WCGOZPBSSA-N
InChI=1S/C32H38N2O8/c1-37-24-12-17(13-25(38-2)29(24)39-3)31(35)42-26-14-18-16-34-11-10-20-19-8-6-7-9-22(19)33-28(20)23(34)15-21(18)27(30(26)40-4)32(36)41-5/h6-9,12-13,18,21,23,26-27,30,33H,10-11,14-16H2,1-5H3/t18-,21+,23-,26-,27+,30+/m1/s1
Molecular Formula | C32H38N2O8 |
Molecular Weight | 578.6527 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugbank.ca/drugs/DB01089
Sources: https://www.drugbank.ca/drugs/DB01089
Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure and for the relief of psychotic behavior. Rauwolfia alkaloids work by controlling nerve impulses along certain nerve pathways. As a result, they act on the heart and blood vessels to lower blood pressure. Deserpidine's mechanism of action is through inhibition of the ATP/Mg2+ pump responsible for the sequestering of neurotransmitters into storage vesicles located in the presynaptic neuron. The neurotransmitters that are not sequestered in the storage vesicle are readily metabolized by monoamine oxidase (MAO) causing a reduction in catecholamines.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1893 Sources: https://www.drugbank.ca/drugs/DB01089 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.drugbank.ca/drugs/DB01089 |
Primary | HARMONYL Approved UseFor the treatment of hypertension. Launch Date-4.00896E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
172 pg/mL |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DESERPIDINE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4193 pg × h/mL |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DESERPIDINE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
42.9 h |
0.25 mg single, oral dose: 0.25 mg route of administration: Oral experiment type: SINGLE co-administered: |
DESERPIDINE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
6 mg 3 times / day multiple, oral (max) Highest studied dose Dose: 6 mg, 3 times / day Route: oral Route: multiple Dose: 6 mg, 3 times / day Sources: Page: p.1115 |
unhealthy n = 13 Health Status: unhealthy Condition: Schizophrenia Sex: M Population Size: 13 Sources: Page: p.1115 |
PubMed
Title | Date | PubMed |
---|---|---|
Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. | 1991 Jan-Feb |
|
Protein kinase C suppresses spontaneous, transient, outwards K+ currents through modulation of the Na/Ca exchanger in guinea-pig gastric myocytes. | 2001 Jan |
|
Muscarinic excitation-contraction coupling mechanisms in tracheal and bronchial smooth muscles. | 2001 Sep |
|
Extensive skinning of cell membrane diminishes the force-inhibiting effect of okadaic acid on smooth muscles of Guinea pig hepatic portal vein. | 2002 Apr |
|
Dependence of Ca2+-induced contraction on ATP in alpha-toxin-permeabilized preparations of rat femoral artery. | 2003 Oct |
|
Nitric oxide relaxes rat tail artery smooth muscle by cyclic GMP-independent decrease in calcium sensitivity of myofilaments. | 2004 Aug |
|
Inhibition by cytoplasmic nucleotides of a new cation channel in freshly isolated human and rat type II pneumocytes. | 2004 Dec |
|
Ca2+-independent hypoxic vasorelaxation in porcine coronary artery. | 2005 Feb 1 |
|
Synthesis of deserpidine from reserpine. | 2005 Nov |
|
Involvement of Rho kinase and protein kinase C in carbachol-induced calcium sensitization in beta-escin skinned rat and guinea-pig bladders. | 2006 Jun |
|
Intracellular calcium stores in beta-escin skinned rat and guinea-pig bladders. | 2007 Jul 2 |
|
Dynamic modulation of intracellular glucose imaged in single cells using a FRET-based glucose nanosensor. | 2008 May |
|
Beta-escin, a natural triterpenoid saponin from Chinese horse chestnut seeds, depresses HL-60 human leukaemia cell proliferation and induces apoptosis. | 2008 Sep |
|
Brain Activation by Peptide Pro-Leu-Gly-NH(2) (MIF-1). | 2010 |
|
Calcium sensitization induced by sodium fluoride in permeabilized rat mesenteric arteries. | 2010 Feb |
|
Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. | 2010 Jul |
|
Beta-escin has potent anti-allergic efficacy and reduces allergic airway inflammation. | 2010 May 21 |
|
KMUP-1 ameliorates monocrotaline-induced pulmonary arterial hypertension through the modulation of Ca2+ sensitization and K+-channel. | 2010 May 8 |
|
Parameters of Reserpine Analogs That Induce MSH2/MSH6-Dependent Cytotoxic Response. | 2010 Sep 13 |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:13:33 UTC 2023
by
admin
on
Fri Dec 15 15:13:33 UTC 2023
|
Record UNII |
9016E3VB47
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C270
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
||
|
WHO-ATC |
C02LA03
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
||
|
NDF-RT |
N0000175650
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
||
|
WHO-VATC |
QC02AA05
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
||
|
NDF-RT |
N0000175640
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
||
|
WHO-VATC |
QC02LA03
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
||
|
LIVERTOX |
281
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
||
|
WHO-ATC |
C02AA05
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID8020383
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | |||
|
DB01089
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | |||
|
100000083187
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | |||
|
7064
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | |||
|
205-004-8
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | |||
|
810
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | |||
|
C100104
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | |||
|
m4189
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | Merck Index | ||
|
C61699
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | |||
|
656
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | |||
|
131-01-1
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | |||
|
9016E3VB47
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | |||
|
CHEMBL1200515
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | |||
|
72138
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | |||
|
8550
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | |||
|
DESERPIDINE
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | |||
|
62174
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | RxNorm | ||
|
SUB06992MIG
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY | |||
|
27478
Created by
admin on Fri Dec 15 15:13:33 UTC 2023 , Edited by admin on Fri Dec 15 15:13:33 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |